WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 527092
CAS#: 627865-18-3 (rotation +)
Description: CAY10471, also known as TM30089, is a potent and selective long-lasting antagonist of CRTH2. Cat#527092 is a + rotation. isomer (note sure it is a R-isomer or S-isomer).
MedKoo Cat#: 527092
Name: CAY10471
CAS#: 627865-18-3 (rotation +)
Chemical Formula: C21H21FN2O4S
Exact Mass: 416.1206
Molecular Weight: 416.4674
Elemental Analysis: C, 60.56; H, 5.08; F, 4.56; N, 6.73; O, 15.37; S, 7.70
Related CAS #: 627865-18-3 (rotation +) 844639-57-2 (racemic)
Synonym: CAY-10471; CAY 10471; CAY10471; TM30089; TM-30089; TM 30089
IUPAC/Chemical Name: (+)-3-[[(4-fluorophenyl)sulfonyl]methylamino]-1,2,3,4-tetrahydro-9H-carbazole-9-acetic acid
InChi Key: CANCTKXGRVNXFP-UHFFFAOYSA-N
InChi Code: InChI=1S/C21H21FN2O4S/c1-23(29(27,28)16-9-6-14(22)7-10-16)15-8-11-20-18(12-15)17-4-2-3-5-19(17)24(20)13-21(25)26/h2-7,9-10,15H,8,11-13H2,1H3,(H,25,26)
SMILES Code: O=C(O)CN1C2=C(C3=C1C=CC=C3)CC(N(S(=O)(C4=CC=C(F)C=C4)=O)C)CC2
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 416.4674 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Ma J, Yang Q, Wei Y, Yang Y, Ji C, Hu X, Mai S, Kuang S, Tian X, Luo Y, Liang G, Yang J. Effect of the PGD2-DP signaling pathway on primary cultured rat hippocampal neuron injury caused by aluminum overload. Sci Rep. 2016 Apr 19;6:24646. doi: 10.1038/srep24646. PubMed PMID: 27089935; PubMed Central PMCID: PMC4835855.
2: Ito H, Yan X, Nagata N, Aritake K, Katsumata Y, Matsuhashi T, Nakamura M, Hirai H, Urade Y, Asano K, Kubo M, Utsunomiya Y, Hosoya T, Fukuda K, Sano M. PGD2-CRTH2 pathway promotes tubulointerstitial fibrosis. J Am Soc Nephrol. 2012 Nov;23(11):1797-809. doi: 10.1681/ASN.2012020126. Epub 2012 Sep 20. PubMed PMID: 22997255; PubMed Central PMCID: PMC3482731.
3: Yue L, Durand M, Lebeau Jacob MC, Hogan P, McManus S, Roux S, de Brum-Fernandes AJ. Prostaglandin D2 induces apoptosis of human osteoclasts by activating the CRTH2 receptor and the intrinsic apoptosis pathway. Bone. 2012 Sep;51(3):338-46. doi: 10.1016/j.bone.2012.06.003. Epub 2012 Jun 12. PubMed PMID: 22705147.
4: Nakahigashi K, Doi H, Otsuka A, Hirabayashi T, Murakami M, Urade Y, Zouboulis CC, Tanizaki H, Egawa G, Miyachi Y, Kabashima K. PGD2 induces eotaxin-3 via PPARγ from sebocytes: a possible pathogenesis of eosinophilic pustular folliculitis. J Allergy Clin Immunol. 2012 Feb;129(2):536-43. doi: 10.1016/j.jaci.2011.11.034. Epub 2011 Dec 28. Erratum in: J Allergy Clin Immunol. 2014 Feb;133(2):604. Zouboulis, Christos C [added]. PubMed PMID: 22206772.
5: Ebersberger A, Natura G, Eitner A, Halbhuber KJ, Rost R, Schaible HG. Effects of prostaglandin D2 on tetrodotoxin-resistant Na+ currents in DRG neurons of adult rat. Pain. 2011 May;152(5):1114-26. doi: 10.1016/j.pain.2011.01.033. Epub 2011 Feb 22. PubMed PMID: 21345590.
6: Lin TA, Kourteva G, Hilton H, Li H, Tare NS, Carvajal V, Hang JS, Wei X, Renzetti LM. The mRNA level of Charcot-Leyden crystal protein/galectin-10 is a marker for CRTH2 activation in human whole blood in vitro. Biomarkers. 2010 Nov;15(7):646-54. doi: 10.3109/1354750X.2010.511266. Epub 2010 Sep 21. PubMed PMID: 20858065.
7: Hatanaka M, Shibata N, Shintani N, Haba R, Hayata A, Hashimoto H, Baba A. 15d-prostaglandin J2 enhancement of nerve growth factor-induced neurite outgrowth is blocked by the chemoattractant receptor- homologous molecule expressed on T-helper type 2 cells (CRTH2) antagonist CAY10471 in PC12 cells. J Pharmacol Sci. 2010;113(1):89-93. Epub 2010 Apr 16. PubMed PMID: 20424389.
8: Satarug S, Wisedpanichkij R, Takeda K, Li B, Na-Bangchang K, Moore MR, Shibahara S. Prostaglandin D2 induces heme oxygenase-1 mRNA expression through the DP2 receptor. Biochem Biophys Res Commun. 2008 Dec 19;377(3):878-83. doi: 10.1016/j.bbrc.2008.10.094. Epub 2008 Oct 26. PubMed PMID: 18957281.
9: Schuligoi R, Sedej M, Waldhoer M, Vukoja A, Sturm EM, Lippe IT, Peskar BA, Heinemann A. Prostaglandin H2 induces the migration of human eosinophils through the chemoattractant receptor homologous molecule of Th2 cells, CRTH2. J Leukoc Biol. 2009 Jan;85(1):136-45. doi: 10.1189/jlb.0608387. Epub 2008 Oct 3. PubMed PMID: 18835884.
10: Royer JF, Schratl P, Lorenz S, Kostenis E, Ulven T, Schuligoi R, Peskar BA, Heinemann A. A novel antagonist of CRTH2 blocks eosinophil release from bone marrow, chemotaxis and respiratory burst. Allergy. 2007 Dec;62(12):1401-9. Epub 2007 Aug 21. PubMed PMID: 17714552.
